IR contact details Carla Bretes Director Investor Relations and Business Development e: ir@moonlaketx.com Upcoming events Sep 4 - Sep 7 2024 ESDR (European Society of Dermatological Research) Sep 5 - Sep 7 2024 International SpA Congress Sep 17 - Sep 19 2024 Cantor, Global Healthcare Conference View All Events View All Events + Corporate presentations MoonLake R&D Day 10th March View All Presentations View All Presentations + Latest press releases Jun 10 2024 MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis May 16 2024 MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa May 07 2024 MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update View All News View All Press Releases +
Jun 10 2024 MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
May 16 2024 MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 07 2024 MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update